US researchers have found evidence to support catch-up vaccination against the human papillomavirus in women given their first dose in older adolescence.
Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.
Michael Schweizer (University of Washington, Seattle, USA) outlines a new therapy that utilizes both androgen deprivation and administration, which may potentially have benefit for prostate cancer patients.
US researchers have found evidence to support catch-up vaccination against the human papillomavirus in women given their first dose in older adolescence.
Source:
Lancet Child Adolesc Health 2018; doi:10.1016/S2352-4642(18)30220-7 Lancet Child Adolesc Health 2018; doi: 10.1016/S2352-4642(18)30268-2
The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.
Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.
Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.
Patients with a history of cancer who receive tumor necrosis factor inhibitors for rheumatoid arthritis may not be at increased risk for recurrence, suggests a Swedish population-based study.
Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
